Drug Profile

CK 0802

Alternative Names: CK-0802

Latest Information Update: 28 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellenkos
Class Immunotherapies; T lymphocyte cell therapies
Mechanism of Action T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Lung disorders; SARS-CoV-2 acute respiratory disease

Most Recent Events

28 Aug 2026 No recent reports of development identified for phase-I development in Lung disorders in Unknown (IV)
11 May 2026 Cellenkos plans a phase Ib/IIa trial for steroid-refractory graft-versus-host disease (GVHD) (In Children, In adolescents, In adults, In the elderly, Treatment-experienced) (IV, Infusion) in July 2026 (NCT07576699)
04 May 2026 US FDA approves IND application for CK 0802 in Graft-versus-host disease

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com